PSPrabhsimranjot Singh

Prabhsimranjot Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Prabhsimranjot Singh has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Abiraterone-Associated Fulminant Liver Failure

    by Prabhsimranjot Singh, Ankur Sinha, Tsering G. Lama Tamang, Abhinav B. Chandra, Yiwu Jim Huang


  • Open Access

    Synchronous Hodgkin's lymphoma and seminoma: a rare coexistence and an important lesson

    by Prabhsimranjot Singh, Sudhamshi Toom, Makhardwaj Shrivastava, Jason Shaw, David Silver, Jasminka Balderacchi, Jay Lipshitz

    Key Clinical Message: Synchronous presentation of seminoma and lymphoma is rare but has important ramifications for the treatment of both malignancies. Without clinical vigilance, this situation may be easily missed, leading to inappropriate management. We describe a patient with synchronous seminoma and Hodgkin's lymphoma and discuss the implication on his treatment.


  • Very Severe Aplastic Anemia During Treatment With Doxycycline

    by Prabhsimranjot Singh, Ankur Sinha, Anisha Kamath, Sonali Malhotra


  • Open Access

    Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer

    by Prabhsimranjot Singh, Sudhamshi Toom, Yiwu Huang

    Targeted therapy and immunotherapy have revolutionized treatment of various cancers in the past decade. Despite targeted therapy with trastuzumab in Her2-positive gastric cancer patients, survival has been dismal, mostly due to disease progression and toxicity related to the treatments. One area of active development is looking for ideal monoclonal antibodies (IMAB) specific to the proteins only on the tumor and hence avoiding unnecessary side effects. Claudin proteins with isoform 2 are one such protein, specific for several cancers, particularly gastric cancer and its metastases, leading to the development of anti-claudin 18.2 specific antibody, claudiximab. This review will highlight the latest development of claudiximab as first in class IMAB for the treatment of gastric cancer.


  • Open Access

    Prostatic Lymphoma Masquerading as Urinary Retention and Hematuria With Review of Literature

    by Tsering Gyalpo Lama Tamang, Prabhsimranjot Singh, Jonathan Garellek, Sonali Malhotra, Abhinav Binod Chandra, William Solomon

    Lymphomas of prostate are very rare tumors. They are not commonly considered in the clinical and histological differential diagnosis of prostatic enlargement. We report a case of a 49-year-old man who presented to emergency department with several weeks of difficulty in urination, for which he was being treated for benign prostate hyperplasia with no improvement. Computerized tomography scan showed lobulated mass originating from the superior aspect of the prostate with right inguinal lymph node involvement and no distant organ metastatic disease. Prostatic biopsy revealed diffuse large B-cell lymphoma. The patient achieved complete remission after six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen. Lymphomas of the prostate should be considered in differential diagnosis of the patient presenting with obstructive lower urinary tract symptoms especially in patients with normal prostatic-specific antigen level and previous history of lymphoma in other sites.


  • Open Access

    Rare Case of Spinal Cord Compression as Initial Presentation of Thymic Carcinoma

    by Prabhsimranjot Singh, Ankur Sinha, Sonali Malhotra, Abhinav Binod Chandra, William Solomon, Yiwu Huang

    Thymic carcinomas are rare aggressive cancers with limited clinical trial data. Its usual treatment is surgical resection with variable response to chemotherapy and radiation. It usually presents as anterior mediastinal mass with late sequela of metastases to the lymph nodes, pleura and bones. We present of thymic carcinoma with a rare initial presentation of vertebral metastases causing spinal cord compression.

  • Subsequent cancers in the long term survivors of Hodgkin’s lymphoma: A SEER based analysis.

    by Prabhsimranjot Singh, Vivek Kumar, Neha Chaudhary, Parita Soni, Abhinav Binod Chandra

    E19014 Background: The impact of newer radiotherapy techniques and non-alkylating agent based regimens (ABVD and Stanford V) on subsequent cancers in Hodgkin’s lymphoma (HL) survivors remains unclear. Recently a study conducted outside United States (US) reported no change in the risk. This study aimed to compare the rate of subsequent cancers in the HL survivors in US with the general population and to compare the rates in survivors diagnosed before and after the introduction of newer treatment modalities. Methods: The HL patients diagnosed in 1973-1992 and survived beyond 5 years were identified in the Surveillance, Epidemiology and End results (SEER) database. We compared the risk of subsequent cancers with the risk expected in general population and compared the incidence rates in survivors diagnosed in 1973-82 and 1983-92. Results: With a follow-up of 8,662 HL survivors for 151,443 person-years (PY), 2068 subsequent cancers were diagnosed, with standardized incidence ratio (SIR) of 2.53 (95% CI, 2.42-2.64). Lung (SIR 3.80; CI 3.43-4.21) and female breast cancers (SIR 3.45; CI 3.12-3.8) were the commonest. The risk was increased for all cancer types with the highest risk for tumors of salivary gland (SIR 11.68; CI 7.56-17.25), acute myeloid leukemia (AML) (SIR 10.76; CI 7.56-17.25), soft tissue including heart (SIR 9.45; CI 6.92-12.6), non-Hodgkin’s lymphoma (NHL) (SIR 5.02; CI 4.29-5.84) and thyroid (SIR 4.58; CI 3.68-5.65). The risk was highest 15-20 years after diagnosis (SIR, 2.68; CI, 2.51 to 2.87). In the cohort diagnosed in 1973-82, 1111 cancers were diagnosed in 3994 patients (SIR 2.76; 2.6-2.93) while 957 cancers were diagnosed in 5220 patients (SIR 2.27; 2.13-2.42) diagnosed in 1983-92 (P = 0.03). The incidence of thyroid cancers (p = .14), leukemia (p = .46) and NHL (p = .22) was not different. Conclusions: The incidence of subsequent cancers in HL survivors diagnosed after introduction of newer treatment modalities (1983-92) has declined significantly in US. However risk of subsequent hematological malignancies remains unchanged. The risk of secondary cancers is still higher than general population and is maximum 15-20 years after diagnosis. Thus close follow up with active surveillance is crucial for the HL survivors.


  • The incidence, prognosis and survival of primary breast lymphoma: A SEER experience.

    by Vivek Kumar, Prabhsimranjot Singh, Makardhwaj Shrivastava, Abhinav Binod Chandra, Yiqing Xu, William B. Solomon

    E19026 Background: Primary breast lymphoma (PBL) are rare neoplasms involving breasts and draining lymph nodes without evidence of disease elsewhere. By definition PBL are stage IE and IIE non-Hodgkin’s lymphoma (NHL). The staging of bilateral tumors is controversial. We evaluated the trends of incidence and prognosis in PBL. Methods: We analyzed all cases of PBL registered in the Surveillance, Epidemiology, and End Results (SEER) database from 1983 to 2012. Age-adjusted incidence and survival rates were calculated. K-M curves were plotted and log-rank statistics computed to detect differences between survival curves for sex, race, stage, radiation, age, and year of diagnosis. Results:: 1545 cases of PBL were identified. The cumulative age standardized incidence rate per 100, 000 was 0.147. The rate increased with advancing age from .032 per 100,000 (95% CI; .026-.038) in below 50 years old to .767 (95% CI; .66-.89) per 100,000 above 80 years. The incidence rate per 100,000 almost doubled from .094 (95% CI; .08-.11) during 1983-92 to.172 (95%CI; .16-.19) in 2003-12. (p = .02) The median overall survival (OS) (115 months; 95% CI 103-127) was better than all NHL (median OS 97 months; 95% CI 95.6-98.4) (p = .03). 30 patients had bilateral tumors staged as I and II NHL in the SEER database. The outcome in bilateral tumors (median OS 115 months: 95% CI 102.8 – 127.2) was similar to unilateral tumors. Stage I (HR .46-.67) and age below 50 years (HR .05 -.108) were the strongest predictors of favorable outcome on multivariate analysis. (P = 0.00) Histological type didn’t affect the prognosis in PBL unlike in NHL. (P = 0.15). Median OS increased from 51 months (95% CI; 55-95) during 1983-92 to 124 months (95% CI; 103-127) in 2003-12 (p = .03). No differences were seen in the distribution of stage or age at diagnosis among these time periods. Conclusions: The incidence of PBL is increasing in United States. The prognosis of bilateral tumors is similar to the stage I and II unilateral tumors and thus current view of staging bilateral tumors as stage IV may not be valid. The survival of PBL patients is better than NHL and continues to improve. Prognosis is not affected by histological type unlike in NHL. Age and stage are the strongest predictors of outcome in PBL.

  • Open Access

    Chronic Myeloid Leukemia in a Patient With Multiple Sclerosis Treated With Interferon Beta-1a

    by Tsering Gyalpo Lama Tamang, Prabhsimranjot Singh, Abhinav Binod Chandra